North American Scientific Completes Sale of Non-Therapeutic Product Line
North American Scientific, Inc. announced that it has completed the sale of its Non-Therapeutic Product Line to Eckert & Ziegler Isotope Products, Inc.
"We have successfully closed this transaction in the expected time frame and we are now focused on the therapeutic areas of our business with our Prospera and ClearPath product lines for local radiation treatment for the prostate and breast cancer patient," said John Rush, President and CEO of North American Scientific. "The proceeds from the sale of this product line will provide the Company with important non-dilutive capital to invest in ongoing operations."
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Beckman Coulter Announces the Creation of Beckman Coulter Genomics - New Company Offers Comprehensive Genomic Services
Bruker to acquire the NanoString business in an asset deal
Ultrasonic Scientific Expands its Operations with the Appointments of Italien and Japanese Distributors
DNTOX receives €1.4 million seed funding for non-animal testing of chemicals - The new capital will be used to set up the test laboratories in Düsseldorf, aim for GLP accreditation and launch the test battery on the market
Oxford Instruments announces major technology licensing deal with GE Healthcare - Result will be powerful new tool for in vitro molecular analysis